Top Markets
Coin of the day
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation

ADMP
株式のランク #38725
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company... Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.
株価
$0.6241
最終同期: 2023-10-03
時価総額
$836.88K
変化(1日)
-2.10%
変化(1年)
0.00%
US
取引 Adamis Pharmaceuticals Corporation (ADMP)

カテゴリー

Adamis Pharmaceuticals Corporation(ADMP)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
Adamis Pharmaceuticals Corporation の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
Adamis Pharmaceuticals Corporation の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。